Cian Healthcare Past Earnings Performance
Past criteria checks 3/6
Cian Healthcare has been growing earnings at an average annual rate of 20.3%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 3.7% per year. Cian Healthcare's return on equity is 0.1%, and it has net margins of 0.1%.
Key information
20.3%
Earnings growth rate
23.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -3.7% |
| Return on equity | 0.1% |
| Net Margin | 0.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cian Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 634 | 1 | 102 | 0 |
| 30 Jun 23 | 661 | 11 | 102 | 0 |
| 31 Mar 23 | 687 | 20 | 101 | 0 |
| 31 Dec 22 | 689 | -7 | 108 | 0 |
| 30 Sep 22 | 690 | -34 | 114 | 0 |
| 30 Jun 22 | 735 | -45 | 109 | 0 |
| 31 Mar 22 | 781 | -55 | 104 | 0 |
| 31 Dec 21 | 800 | -30 | 93 | 0 |
| 30 Sep 21 | 820 | -6 | 81 | 0 |
| 30 Jun 21 | 779 | -2 | 80 | 0 |
| 31 Mar 21 | 739 | 1 | 78 | 0 |
| 31 Dec 20 | 704 | -22 | 28 | 0 |
| 30 Sep 20 | 668 | -28 | 162 | 0 |
| 30 Jun 20 | 621 | -33 | 158 | 0 |
| 31 Mar 20 | 573 | -38 | 49 | 0 |
| 31 Dec 19 | 586 | -37 | 90 | 0 |
| 30 Sep 19 | 601 | -42 | 76 | 0 |
| 30 Jun 19 | 617 | -18 | 69 | 0 |
| 31 Mar 19 | 634 | 7 | 62 | 0 |
| 31 Mar 18 | 596 | 40 | 48 | 0 |
| 31 Mar 17 | 518 | 23 | 46 | 0 |
| 31 Mar 16 | 471 | 15 | 46 | 0 |
Quality Earnings: 542678 has high quality earnings.
Growing Profit Margin: 542678 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 542678 has become profitable over the past 5 years, growing earnings by 20.3% per year.
Accelerating Growth: 542678 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 542678 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 542678's Return on Equity (0.1%) is considered low.